Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Best corrected visual acuity (BCVA) ≥23 ETDRS letters in study eye~* Evidence of active choroidal neovascularisation (CNV) involving the center of the fovea in study eye Patient subgroup specific inclusion criteria: - Group 1. Primary treatment failure~* Initiated treatment with aflibercept \<130 days prior to the Screening Visit.~* No increase in BCVA (≥5 letters) since commencing treatment with aflibercept.~* Disease activity has never been controlled in the study eye after initiating aflibercept as defined by at least one of the following: evidence of unchanged or increasing retinal or subretinal fluid; new PED; unchanged or increasing size of preexisting PED.~Group 2. Suboptimal treatment response~* Aflibercept commenced ≥6 months prior to the Screening Visit.~* Received ≥3 aflibercept injections into the study eye within 6 months of the Screening Visit.~* Evidence of previous reduced disease activity (as defined by reduction of ≥50μm in Central Subfield Retinal Thickness on OCT) noted in the study eye after initiating aflibercept.~* At Screening Visit, disease activity has worsened (as defined by increasing retinal\* or subretinal fluid, or new or increasing size of PED) in the study eye compared to prior visits.~Exclusion Criteria:~* History of cerebrovascular accident, transient ischemic attack or myocardial infarction within 3 months of the Screening visit.~* Uncontrolled blood pressure~* Evidence of bilateral active CNV during the Screening Period or at Baseline requiring bilateral antiVEGF injections.~* Prior intravitreal injection of ranibizumab or bevacizumab into the study eye and/or prior intravitreal injection of bevacizumab into the fellow eye.~* Cataract (if causing significant visual impairment), aphakia, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization of any other cause than wet AMD (e.g. ocular histoplasmosis, pathologic myopia (≥8 dioptres)) at the time of Screening and Baseline.~* Irreversible structural damage involving the center of the fovea (e.g. advanced fibrosis or geographic atrophy) which in the opinion of the Investigator is sufficient to irreversibly impair visual acuity.~* Polypoidal choroidal vasculopathy (PCV), RPE tear, central serous retinopathy (CSR), or significant vitreomacular traction identified during Screening period or within 4 months of Baseline visit.~* Unable to obtain at Screening OCT images of sufficient quality to be analyzed

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.

Based on this trial design, predict the completion outcome and termination type (if applicable).